



भारतीय कृषि अनुसंधान परिषद
Indian Council of Agricultural Research
केन्द्रीय समुद्री मात्स्यिकी अनुसंधान संस्थान
Central Marine Fisheries Research Institute



(कृषि अनुसंधान एवं शिक्षा विभाग, कृषि एवं किसान कल्याण मंत्रालय, भारत सरकार)
(Department of Agricultural Research and Education, Ministry of Agriculture and Farmers' Welfare, Govt. of India)
पोस्ट बॉक्स नं. 1603, एरणाकुलम नॉर्थ पी.ओ., कोच्ची - 682 018, केरल, भारत
Post Box No. 1603, Ernakulam North P.O., Kochi - 682 018, Kerala, India
Phone: 91 484 2394867/2391407, Fax: 91 484 2394909/2396685, Email: director.cmfri@icar.gov.in, Web: www.cmfri.org.in

CMFRI Platinum Jubilee - Celebrating 70 years of Excellence in Research

F. No. 14-6/2021-Cdn.

Dated:04.09.2023

EXPRESSION OF INTEREST

The Director, Central Marine Fisheries Research Institute, P.B. No.1603, Ernakulam North P.O., Kochi - 682 018 invites sealed tenders from the competitive bidders to out-license **Cadalmin™ Antihypercholesterolemic** nutraceutical product for dyslipidaemia and **Cadalmin™ Immunalgin** to boost the innate immunity from seaweed developed by ICAR-CMFRI. Tender documents issued by this Office or downloaded from our official website (www.cmfri.org.in) only will be accepted. Interested registered companies (Private or public) with proven tract record may send the tender by post in the prescribed format (as detailed at our website www.cmfri.org.in) to the address (The Director Research Institute, P No. 1603, Ernakulam North P. O., Kochi - 682 018, Kerala), from 25 days of publication of the advertisement.

Head of Office



Expression of Interest – Cadalmin™ Antihypercholesterolemic extract (ACe), and Cadalmin™ Immunalgin extract (Cadalmin™ IMe) developed by CMFRI, Kochi, Kerala

October 16, 2020

Central Marine Fisheries Research Institute (CMFRI), Kochi invites Expression of Interest (Eoi) to out license the following two nutraceutical products developed by the Institute from seaweeds to the registered companies with proven track record:

- 1) Cadalmin™ Antihypercholesterolemic extract (ACe) a novel to anti-dyslipidemic nutraceutical*
- 2) Cadalmin™ Immunalgin extract (Cadalmin™ IMe) Nutraceutical to improve immune system**

These nutraceutical products has been scientifically evaluated and all research documentation is available with the Institute.

* Cadalmin™ Antihypercholesterolemic extract (Cadalmin™ ACe) is a nutraceutical product as a natural remedy for dyslipidemia from seaweed. The bioactive ingredients in Cadalmin™ ACe competitively inhibit hydroxymethyl glutaryl coenzyme A reductase, various target receptors and other limiting enzymes, thereby hindering the occurrence of dyslipidemia. Attenuates high fat-induced hyperlipidemia, characterized by a significantly lower level of serum LDL, lipid peroxidation status and lower atherogenic index. Cadalmin™ ACe has no side effects as proved from the preclinical and acute/long-term chronic toxicity studies. The efficacy of the product was compared with that of a standard drug (Atorvastatin™) through animal test models. Preclinical trials demonstrated a lack of test substance-related general organ or systemic toxicity following oral administration at a dose as high as 2000 mg/kg/d.

** Cadalmin™ Immunalgin extract (Cadalmin™ IMe) is a seaweed-based nutraceutical product, which is a 100% natural blend of bioactive ingredients extracted with ecofriendly 'green' technology to boost the innate immunity. Cadalmin™ IMe elevates innate immune responses by the regulation of the secretion of pro-inflammatory cytokines and chemokines. Cadalmin™ IMe exhibited the immunomodulatory potential by increasing bone marrow stem cell differentiation, α-esterase activity, and lymphocyte blastogenesis in immunosuppressed subject. TCP-3 also induced antiviral and immune activation by upregulating serum IFN-γ and IL-2 levels in immunosuppressed animals. Anti-inflammatory activities of sulfated galactofucan were exhibited by regulating the secretion of pro-inflammatory cytokines, such as TNF-α, IL-6/1β,12, TGF-β, and NO in different in vitro and in vivo models. Cadalmin™ IMe has no side effects (LD50 > 4000 mg/kg BW) as proved from the acute/long term chronic toxicity studies on experimental subjects.

Interested registered companies (private or public) with proven track record may contact or send expression of interest by post in the prescribed format to the following address within 25 days of publication of this advertisement.

The Director

(Kind Attention: Assistant Administrative Officer-Coordination)

Central Marine Fisheries Research Institute, Ernakulam North P.O., Kochi-18, Kerala

Format for Expression of Interest (Eoi)

Name of the firm	Address	Brief profile of the firm concerned	Licence Fee (Onetime payment for a period....years)	Royalty (% of profit that can be shared with CMFRI)	Any other mode of collaboration/licensing with detailed justification

Terms and conditions

- The company should optimize the product production according to CMFRI inputs
- Bear all costs involved in trial runs
- The company will also have the exclusive marketing rights in India for online sales for the specified duration of license, bulk sales and retail sales only in India
- Marketing abroad shall require approvals from CMRI/ICAR/ Govt. of India on mutually agreed terms
- Licensee will have R & D support of CMFRI during the period of licence
- Formulations and source of all raw material will be provided by the Institute
- The highest bidder will be selected for entering into a memorandum of understanding (MoU)
- Selection of the bidders may be also at the discretion of the Director CMFRI, if required
- There is no bidding fee and the company with whom CMFRI enters into an MoU shall be published in the website of CMFRI www.cmfri.org.in within 60 days of signing of the MoU
- An existing licensee of CMFRI should appraise the worth of the earlier out-licensed products.
- Correspondences from unsuccessful bidders cannot be entertained.

Director CMFRI Cochin



Expression of Interest – Cadalmin™ Antihypercholesterolemic extract (ACe), and Cadalmin™ Immunalgin extract (Cadalmin™ IMe) developed by CMFRI, Kochi, Kerala

Format for open advertisement in newspapers and CPP Portals

Tender Enquiry No. ITMU/CMFRI/OL-4/2023-2023

Dated: 02nd August 2023

The Director, Central Marine Fisheries Research Institute, PB No. 1603, Ernakulam North P.O., Kochi-682 018 invites sealed tenders from the competitive bidders to out-license 1) Cadalmin™ Antihypercholesterolemic extract (ACe): a novel to anti-dyslipidemic nutraceutical and Cadalmin™ Immunalgin extract (Cadalmin™ IMe): Nutraceutical to improve immune system developed by ICAR-Central Marine Fisheries Research Institute. Tender document issued by this office or downloaded from our official website (www.cmfri.org.in) only be accepted. **Interested registered companies** (private or public) with proven track record may send the tender by post in the prescribed format (as detailed at our official web site www.cmfri.org.in) to the address **(The Director (kind attention: Assistant Administrative Officer-Coordination), Central Marine Fisheries Research Institute, PB No. 1603, Ernakulam North P.O., Kochi-682 018, Kerala)**, from 25 days of publication of the advertisement.

Director CMFRI Cochin